1-piperidin-1-yl-3,4-dihydro-2H-quinoline

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 1-piperidin-1-yl-3,4-dihydro-2H-quinoline
• 化学式: C₁₄H₂₀N₂
• 分子量: 216.32
• InChiKey: STWMVDMOJPLMPX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  16
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  6.5
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• SUBSTITUTED PIPERIDINYL-TETRAHYDROQUINOLINES
  申请人：Bayer Pharma Aktiengesellschaft

  公开号：US20160318901A1

  公开（公告）日：2016-11-03

  The present application relates to novel substituted piperidinyltetrahydroquinolines, to processes for their preparation, to their use for the treatment and/or prevention of diseases and to their use for preparing medicaments for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of diabetic microangiopathies, diabetic ulcers on the extremities, in particular for promoting wound healing of diabetic foot ulcers, diabetic heart failure, diabetic coronary microvascular heart disorders, peripheral and cardial vascular disorders, thromboembolic disorders and ischaemias, peripheral circulatory disturbances, Raynaud's phenomenon, CREST syndrome, microcirculatory disturbances, intermittent claudication, and peripheral and autonomous neuropathies.

  本申请涉及新颖的取代哌啶基四氢喹啉化合物，以及它们的制备方法，其用于治疗和/或预防疾病，并用于制备治疗和/或预防疾病的药物，特别是用于治疗和/或预防糖尿病微血管病变、四肢糖尿病溃疡，特别是促进糖尿病足溃疡愈合、糖尿病心力衰竭、糖尿病冠状微血管心脏疾病、周围和心脏血管疾病、血栓栓塞疾病和缺血症、周围循环障碍、雷诺现象、CREST综合征、微循环障碍、间歇性跛行以及周围和自主神经病变的治疗和/或预防。
• SUBSTITUTED PIPERIDINYLTETRAHYDROQUINOLINES
  申请人：BAYER PHARMA AKTIENGESELLSCHAFT

  公开号：US20160304491A1

  公开（公告）日：2016-10-20

  The present application relates to novel substituted piperidinyltetrahydroquinolines, to processes for their preparation, to their use for the treatment and/or prevention of diseases and to their use for preparing medicaments for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of diabetic microangiopathies, diabetic ulcers on the extremities, in particular for promoting wound healing of diabetic foot ulcers, diabetic heart failure, diabetic coronary microvascular heart disorders, peripheral and cardial vascular disorders, thromboembolic disorders and ischaemias, peripheral circulatory disturbances, Raynaud's phenomenon, CREST syndrome, microcirculatory disturbances, intermittent claudication, and peripheral and autonomous neuropathies.

  本申请涉及新型取代哌啶基四氢喹啉，其制备方法，其用于治疗和/或预防疾病以及用于制备治疗和/或预防疾病的药物，特别是用于治疗和/或预防糖尿病微血管病变、四肢糖尿病溃疡，特别是促进糖尿病足溃疡伤口愈合，糖尿病心力衰竭，糖尿病冠脉微血管心脏疾病，周围和心脏血管疾病，血栓栓塞性疾病和缺血症，周围循环障碍，雷诺现象，CREST综合征，微循环障碍，间歇性跛行以及周围和自主神经病变的治疗和/或预防。
• Substituted piperidinyl tetrahydroquinolines
  申请人：Bayer Pharma Aktiengesellschaft

  公开号：US10323020B2

  公开（公告）日：2019-06-18

  The present application relates to novel substituted piperidinyltetrahydroquinolines, to processes for their preparation, to their use for the treatment and/or prevention of diseases and to their use for preparing medicaments for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of diabetic microangiopathies, diabetic ulcers on the extremities, in particular for promoting wound healing of diabetic foot ulcers, diabetic heart failure, diabetic coronary microvascular heart disorders, peripheral and cardial vascular disorders, thromboembolic disorders and ischaemias, peripheral circulatory disturbances, Raynaud's phenomenon, CREST syndrome, microcirculatory disturbances, intermittent claudication, and peripheral and autonomous neuropathies.

  本申请涉及新型取代的哌啶基四氢喹啉、其制备工艺、其治疗和/或预防疾病的用途以及其制备治疗和/或预防疾病的药物的用途，特别是用于治疗和/或预防糖尿病微血管病变、糖尿病四肢溃疡、特别是用于促进糖尿病足溃疡的伤口愈合、糖尿病性心力衰竭、糖尿病冠状动脉微血管性心脏疾病、外周和心脏血管疾病、血栓栓塞性疾病和缺血、外周循环障碍、雷诺现象、CREST 综合征、微循环障碍、间歇性跛行以及外周和自主神经病变。
• SUBSTITUIERTE PIPERIDINYL-TETRAHYDROCHINOLINE UND IHRE VERWENDUNG ALS ALPHA-2C ADRENOREZEPTOR ANTAGONISTEN
  申请人：Bayer Pharma Aktiengesellschaft

  公开号：EP3083592A2

  公开（公告）日：2016-10-26
• SUBSTITUIERTE PIPERIDINYL-TETRAHYDROCHINOLINE
  申请人：Bayer Pharma Aktiengesellschaft

  公开号：EP3083593A1

  公开（公告）日：2016-10-26